Correlation Between Inozyme Pharma and Immix Biopharma

Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Immix Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Immix Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inozyme Pharma and Immix Biopharma, you can compare the effects of market volatilities on Inozyme Pharma and Immix Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Immix Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Immix Biopharma.

Diversification Opportunities for Inozyme Pharma and Immix Biopharma

0.78

Correlation Coefficient

Inozyme Pharma  Immix Biopharma

Poor diversification

The 3 months correlation between Inozyme and Immix is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Immix Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immix Biopharma and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Immix Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immix Biopharma has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Immix Biopharma go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Immix Biopharma

Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Immix Biopharma. In addition to that, Inozyme Pharma is 1.43 times more volatile than Immix Biopharma. It trades about -0.28 of its total potential returns per unit of risk. Immix Biopharma is currently generating about -0.03 per unit of volatility. If you would invest  210.00  in Immix Biopharma on December 25, 2024 and sell it today you would lose (25.00) from holding Immix Biopharma or give up 11.9% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Inozyme Pharma  vs.  Immix Biopharma

Inozyme Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Immix Biopharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Immix Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Inozyme Pharma and Immix Biopharma

The main advantage of trading using opposite Inozyme Pharma and Immix Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Immix Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immix Biopharma will offset losses from the drop in Immix Biopharma's long position.

The idea behind Inozyme Pharma and Immix Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.